Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Compass Pathways's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $225.74 Mil. Compass Pathways's Total Assets for the quarter that ended in Dec. 2023 was $275.99 Mil.
The historical rank and industry rank for Compass Pathways's Equity-to-Asset or its related term are showing as below:
CMPS'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.94 Med: 0.87 Max: 0.97
Current: 0.82
During the past 6 years, the highest Equity to Asset Ratio of Compass Pathways was 0.97. The lowest was -0.94. And the median was 0.87.
CMPS's Equity-to-Asset is ranked better than 89.4% of 670
companies
in the Healthcare Providers & Services industry
Industry Median: 0.47
vs CMPS: 0.82
Compass Pathways Equity-to-Asset Historical Data
The historical data trend for Compass Pathways's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Compass Pathways's Equity-to-Asset
For the Medical Care Facilities subindustry, Compass Pathways's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Compass Pathways's Equity-to-Asset Distribution in the Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Compass Pathways's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Compass Pathways's Equity-to-Asset falls into.
Compass Pathways Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Compass Pathways's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Compass Pathways Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of Compass Pathways's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Compass Pathways (Compass Pathways) Business Description
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CMPS has been successfully added to your 